DE2205897C3 - Verfahren zur Herstellung von Antithymozytenserum - Google Patents
Verfahren zur Herstellung von AntithymozytenserumInfo
- Publication number
- DE2205897C3 DE2205897C3 DE2205897A DE2205897A DE2205897C3 DE 2205897 C3 DE2205897 C3 DE 2205897C3 DE 2205897 A DE2205897 A DE 2205897A DE 2205897 A DE2205897 A DE 2205897A DE 2205897 C3 DE2205897 C3 DE 2205897C3
- Authority
- DE
- Germany
- Prior art keywords
- serum
- thymus
- animal
- antithymocyte
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000002966 serum Anatomy 0.000 title claims description 67
- 238000000034 method Methods 0.000 title claims description 23
- 230000001494 anti-thymocyte effect Effects 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 10
- 241001465754 Metazoa Species 0.000 claims description 32
- 210000001541 thymus gland Anatomy 0.000 claims description 27
- 241000894007 species Species 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 210000004185 liver Anatomy 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003463 adsorbent Substances 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 7
- 239000006285 cell suspension Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 20
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 239000007853 buffer solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 244000309466 calf Species 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000781 anti-lymphocytic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- 241000192308 Agrostis hyemalis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB427671 | 1971-02-09 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2205897A1 DE2205897A1 (de) | 1972-08-24 |
| DE2205897B2 DE2205897B2 (de) | 1979-08-30 |
| DE2205897C3 true DE2205897C3 (de) | 1980-05-22 |
Family
ID=9774071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2205897A Expired DE2205897C3 (de) | 1971-02-09 | 1972-02-08 | Verfahren zur Herstellung von Antithymozytenserum |
Country Status (18)
| Country | Link |
|---|---|
| AT (1) | AT316743B (enExample) |
| AU (1) | AU460448B2 (enExample) |
| BE (1) | BE778754A (enExample) |
| CA (1) | CA955849A (enExample) |
| CH (1) | CH538866A (enExample) |
| DE (1) | DE2205897C3 (enExample) |
| DK (1) | DK132104C (enExample) |
| ES (1) | ES399465A1 (enExample) |
| FI (1) | FI50203C (enExample) |
| FR (1) | FR2124298B1 (enExample) |
| GB (1) | GB1342391A (enExample) |
| IL (1) | IL38704A (enExample) |
| LU (1) | LU64739A1 (enExample) |
| NL (1) | NL7201683A (enExample) |
| NO (1) | NO137308C (enExample) |
| OA (1) | OA03962A (enExample) |
| RO (1) | RO61514A (enExample) |
| ZA (1) | ZA72825B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006064373A2 (en) * | 2004-12-16 | 2006-06-22 | Genzyme Polyclonals S.A.S. | Methods of purifying immunologlobulins |
-
1971
- 1971-02-09 GB GB427671A patent/GB1342391A/en not_active Expired
-
1972
- 1972-01-28 CH CH124472A patent/CH538866A/fr not_active IP Right Cessation
- 1972-01-28 FR FR7202948A patent/FR2124298B1/fr not_active Expired
- 1972-01-31 BE BE778754A patent/BE778754A/xx not_active IP Right Cessation
- 1972-02-03 ES ES399465A patent/ES399465A1/es not_active Expired
- 1972-02-04 CA CA134,005A patent/CA955849A/en not_active Expired
- 1972-02-04 RO RO69679A patent/RO61514A/ro unknown
- 1972-02-07 LU LU64739D patent/LU64739A1/xx unknown
- 1972-02-07 DK DK52772*#A patent/DK132104C/da not_active IP Right Cessation
- 1972-02-07 AU AU38760/72A patent/AU460448B2/en not_active Expired
- 1972-02-07 IL IL38704A patent/IL38704A/xx unknown
- 1972-02-07 NO NO311/72A patent/NO137308C/no unknown
- 1972-02-08 DE DE2205897A patent/DE2205897C3/de not_active Expired
- 1972-02-08 FI FI720344A patent/FI50203C/fi active
- 1972-02-08 OA OA54493A patent/OA03962A/xx unknown
- 1972-02-08 ZA ZA720825A patent/ZA72825B/xx unknown
- 1972-02-09 AT AT103972A patent/AT316743B/de not_active IP Right Cessation
- 1972-02-09 NL NL7201683A patent/NL7201683A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU3876072A (en) | 1973-08-09 |
| ZA72825B (en) | 1972-10-25 |
| ES399465A1 (es) | 1975-07-01 |
| DE2205897A1 (de) | 1972-08-24 |
| FR2124298A1 (enExample) | 1972-09-22 |
| RO61514A (enExample) | 1976-12-15 |
| CH538866A (fr) | 1973-07-15 |
| NO137308C (no) | 1978-02-15 |
| NL7201683A (enExample) | 1972-08-11 |
| DK132104B (da) | 1975-10-27 |
| DE2205897B2 (de) | 1979-08-30 |
| LU64739A1 (enExample) | 1972-07-03 |
| FI50203B (enExample) | 1975-09-30 |
| IL38704A0 (en) | 1972-04-27 |
| GB1342391A (en) | 1974-01-03 |
| OA03962A (fr) | 1979-08-31 |
| DK132104C (da) | 1976-03-22 |
| NO137308B (no) | 1977-10-31 |
| BE778754A (fr) | 1972-05-16 |
| IL38704A (en) | 1974-12-31 |
| CA955849A (en) | 1974-10-08 |
| FI50203C (fi) | 1976-01-12 |
| AT316743B (de) | 1974-07-25 |
| FR2124298B1 (enExample) | 1975-12-26 |
| AU460448B2 (en) | 1975-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2029499C3 (de) | Verfahren zum Nachweis der Anwesenheit von carcinoembryonalen Antigenen im Blut | |
| CH648330A5 (de) | Tumor-spezifische glykoproteine und verfahren zu deren herstellung. | |
| DE2128670A1 (de) | Immunologische Isoenzym Bestimmungs methode | |
| DE2628468C2 (de) | Verfahren zur Färbung von Basophilen und Reagens zur Durchführung dieses Verfahrens | |
| WO2000024420A1 (de) | Verfahren zur herstellung eines antiviralen mittels | |
| DE3105555A1 (de) | Reagens zum nachweis des rheumatoidfaktors, verfahren zu seiner herstellung und seine verwendung | |
| DE2518474A1 (de) | Mitogenes mittel, verfahren zu seiner herstellung und diese mittel enthaltende arzneimittel und biologische reagenzien | |
| DE2037507A1 (enExample) | ||
| DE2205897C3 (de) | Verfahren zur Herstellung von Antithymozytenserum | |
| DE2054805C3 (de) | Indirekter Hämagglutinationstest bei gleichzeitiger Absorption heterologer Antikörper | |
| DE1617734B1 (de) | Verfahren zur Herstellung eines immunologischen Reagens | |
| DE2732587C2 (enExample) | ||
| DE2742835A1 (de) | Antigenfraktionen von schistosoma mansoni-eiern, geeignet fuer die untersuchung von schistosomiasis | |
| WO2001054707A2 (de) | Veränderung von oberflächenproteomem durch aminopeptidase-inhibitoren | |
| DE19963420A1 (de) | Gewinnung von biologischen Komponenten aus Körperflüssigkeiten | |
| DE2814121B2 (de) | Verfahren zur Herstellung eines bei der Krebs-Diagnose verwendbaren spezifischen Immunserums | |
| EP0141939A2 (de) | Verfahren zur Herstellung von natürlichem Immunoadsorbens | |
| DE4112999C2 (de) | Verfahren und Nachweismittel zum Nachweis einer Infektion mit dem Epstein-Barr Virus | |
| CH617853A5 (en) | Process for the preparation of a tumour polypeptide antigen | |
| EP0013306B1 (de) | Verfahren zur Bestimmung eines opsonierenden oberflächenbindenden alpha-2-Glykoproteins | |
| CH639102A5 (en) | Process for the preparation of recognins, their complexes, of antirecognins and their complexes and use of the complex prepared | |
| DE2744174A1 (de) | Diagnostische zubereitungen aus rotaviren | |
| AT352292B (de) | Verfahren zur bestimmung von infektioesen und immunologischen vorgaengen sowie mittel fuer blutuntersuchungen | |
| DD139903A5 (de) | Testverfahren zur diagnose von malignomen | |
| CH617775A5 (en) | Process for the preparation of antigens from schistosomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8339 | Ceased/non-payment of the annual fee |